menu
Close to 130 industry and non-industry players, across the globe.
The production of radiopharmaceuticals as compared to traditional pharmaceuticals is a multifaceted procedure and requires specialized facilities

 

The production of radiopharmaceuticals ascompared to traditional pharmaceuticals is a multifaceted procedure andrequires specialized facilities, equipment and operational expertise. Further,owing to its inherent hazardous nature, radiopharmaceuticals have a complex regulatorymarket authorization process. Consequently, a number of innovator companieshave demonstrated a preference for outsourcing radiopharmaceuticalmanufacturing to contract service providers.

 

To order this 320+page report, which features 45+ figures and 100+ tables, please visit this - https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html

 

The USD 6+ billion (by 2030)financial opportunity associated with nuclear medicine and radiopharmaceuticalsmanufacturing, has been analyzed across the following segments:

§ Target DiseaseIndication 

  • Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Colorectal Cancer
  • Head and Neck Cancer
  • Lung Cancer
  • Lupus Nephritis
  • Melanoma
  • Multiple Myeloma
  • Primary Sjögren's Syndrome
  • Others 

 

§ Target ImmuneCheckpoint

  • B7-H3
  • CD38
  • CD40
  • CD47
  • Others

 

§ Mechanism of Action

  • Inhibitory
  • Stimulatory

 

§ Therapeutic Modality

  • Monoclonal Antibody
  • Small Molecule

 

§ Type of Therapy 

  • Monotherapy 
  • Combination Therapy

 

§ Route ofAdministration

  • Intravenous
  • Subcutaneous
  • Others

 

§ Key GeographicalRegions 

  • North America
  • Europe
  • Asia-Pacific and the Rest of the World 

 

The NuclearMedicine and Radiopharmaceuticals Manufacturing Market, 2020-2030” report features thefollowing companies, which we identified to be key players in this domain:

§ Advanced AcceleratorApplications

§ Belgian NuclearResearch Center (SCK•CEN)

§ Cardinal Health

§ China Isotope &Radiation Corporation

§ Curium Pharma

§ DuChemBio

§ Eckert & Ziegler

§ Eczacibasi-Monrol

§ GE Healthcare

§ Jubilant DraxImage

§ Lantheus MedicalImaging

§ Nihon Medi-Physics

§ Nordion

§ PETNET Solutions

§ SinoTauPharmaceuticals

§ SOFIE

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction

4. Nuclear Medicine andRadiopharmaceuticals Manufacturers (Industry Players): Current Market Landscape

5. Nuclear Medicine and RadiopharmaceuticalsManufacturers (Non-Industry Players): Current Market Landscape

6. Nuclear Medicine and RadiopharmaceuticalsManufacturers in North America

7. Nuclear Medicine and RadiopharmaceuticalsManufacturers in Europe

8. Nuclear Medicine and RadiopharmaceuticalsManufacturers in Asia-Pacific And Rest of The World

9. Nuclear Medicine andRadiopharmaceuticals Manufacturers: Company Competitiveness Analysis

10. Partnerships and Collaborations

11. Production and Supply Chain of MedicalIsotope Molybdenum-99 (Technetium-99m)

12. Market Forecast and Opportunity Analysis

13. Concluding Remarks

 

14. Executive Insights

 

15. Appendix 1: Tabulated Data

 

16. Appendix 2: List of Companies andOrganizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com